Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals’ stock plummeted 12% after disappointing results from a late-stage trial of a new COPD drug, sparking concerns about the company’s future prospects.

Regeneron Pharmaceuticals’ stock price plummeted 12% after disappointing results from late-stage trials of a new COPD drug, but analysts remain optimistic about the company’s long-term potential.

Regeneron Pharmaceuticals Inc. saw its stock price decline after mixed trial results for its COPD therapy, Itepekimab, but analysts remain optimistic about the company’s long-term prospects.

Regeneron Pharmaceuticals acquires 23andMe for $256 million, aiming to advance shared goals of improving human health and wellness while prioritizing customer data privacy and security.

Regeneron Pharmaceuticals Inc. saw its stock plummet 9-10% after missing earnings expectations, driven by lower-than-expected demand for its flagship product Eylea.

Regeneron Pharmaceuticals Inc. saw its stock plummet 9-10% after missing earnings expectations, driven by lower-than-expected demand for its flagship product Eylea.

Regeneron Pharmaceuticals Inc. saw its stock plummet 10% after a disappointing earnings report, driven by lower-than-expected demand for its flagship product Eylea, which is crucial to the company’s financial health.

Regeneron Pharmaceuticals Inc. made significant strides in the first quarter of 2025, with notable developments in oncology and ophthalmology, solidifying its position as a leader in the biotechnology industry.